ES2071288T3 - Vacuna mejorada de conjugado de polisacarido de meningococos. - Google Patents

Vacuna mejorada de conjugado de polisacarido de meningococos.

Info

Publication number
ES2071288T3
ES2071288T3 ES91900142T ES91900142T ES2071288T3 ES 2071288 T3 ES2071288 T3 ES 2071288T3 ES 91900142 T ES91900142 T ES 91900142T ES 91900142 T ES91900142 T ES 91900142T ES 2071288 T3 ES2071288 T3 ES 2071288T3
Authority
ES
Spain
Prior art keywords
reciprovals
coli
antibodies
modified
polysaccharide conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91900142T
Other languages
English (en)
Inventor
Harold J Jennings
Francis Michon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council Canada
Original Assignee
National Research Council Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council Canada filed Critical National Research Council Canada
Application granted granted Critical
Publication of ES2071288T3 publication Critical patent/ES2071288T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1217—Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

UN POLISACARIDO DEL GRUPO B DE NEISSERIA MENINGITIDIS (GBMP) MODIFICADO PORQUE TIENE GRUPOS DE N-ACETILO CON RESIDUOS DE ACIDO SIALICO SUSTITUIDOS POR GRUPOS DE N-ACILO QUE PRESENTA UNA RESPUESTA INMUNOLOGICA MAYOR AL MISMO. ADEMAS, LA INDUCCION DE LOS ANTICUERPOS QUE REACCIONAN EN CRUZ CON UN MENINGOCOCO DEL GRUPO B NO MODIFICADO Y CON UN POLISACARIDO CAPSULAR DE E. COLI K1 Y OTRAS CELULAS DE LOS TEJIDOS QUE TIENEN UN EPITOPE EN COMUN SE MINIMIZA. LA CONJUGACION DE LOS POLISACARIDOS MODIFICADOS CON UNA PROTEINA FISIOLOGICAMENTE ACEPTABLE COMO POR EJEMPLO TOXOIDES DE TETANOS INDUCE LA PRODUCCION DE ANTICUERPOS PROTECTORES ESPECIFICOS CON NIVELES INSIGNIFICANTES DE ANTICUERPOS REACTIVOS EN CRUZ DE GBMP, PARA ASI CONSEGUIR UNA PROTECCION CONTRA LAS INFECCIONES CAUSADAS POR LOS MENINGOCOCOS DEL GRUPO B Y LA E. COLI K1.
ES91900142T 1989-12-14 1990-12-13 Vacuna mejorada de conjugado de polisacarido de meningococos. Expired - Lifetime ES2071288T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44819589A 1989-12-14 1989-12-14

Publications (1)

Publication Number Publication Date
ES2071288T3 true ES2071288T3 (es) 1995-06-16

Family

ID=23779371

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91900142T Expired - Lifetime ES2071288T3 (es) 1989-12-14 1990-12-13 Vacuna mejorada de conjugado de polisacarido de meningococos.

Country Status (30)

Country Link
US (3) US5576002A (es)
EP (1) EP0504202B1 (es)
JP (1) JP2637845B2 (es)
KR (1) KR0158436B1 (es)
CN (4) CN1049223C (es)
AR (1) AR243934A1 (es)
AT (1) ATE121947T1 (es)
AU (1) AU641715B2 (es)
BR (1) BR9007917A (es)
CA (1) CA2071811C (es)
CZ (1) CZ283530B6 (es)
DE (1) DE69019164T2 (es)
DK (1) DK0504202T3 (es)
ES (1) ES2071288T3 (es)
FI (2) FI104539B (es)
HR (1) HRP920872A2 (es)
HU (2) HU9201966D0 (es)
IE (1) IE68414B1 (es)
IL (1) IL96676A (es)
IN (1) IN171747B (es)
NO (2) NO305275B1 (es)
NZ (1) NZ236471A (es)
PH (1) PH30305A (es)
PL (2) PL166659B1 (es)
RO (1) RO111416B1 (es)
RU (1) RU2105568C1 (es)
SI (1) SI20008B (es)
WO (1) WO1991008772A1 (es)
YU (1) YU24391A (es)
ZA (1) ZA9010065B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648241A (en) * 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
RO111416B1 (ro) * 1989-12-14 1996-10-31 Ca Nat Research Council Polizaharide modificate de neisseria meningitidis si e coli, combinatii antigenice si metoda de imunizare
DE69330464T2 (de) * 1992-09-24 2001-11-08 Brigham And Women's Hospital, Boston Gruppe b streptococcus typ ii und typ v polysaccharid-protein konjugate als impfstoffe
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5700787A (en) * 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5811102A (en) 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
NZ311000A (en) * 1995-06-07 1999-04-29 Smithkline Beecham Biolog Vaccine comprising a polysaccharide antigen-carrier protein conjugate and a free carrier protein
ZA97248B (en) * 1996-01-18 1997-07-18 Rohm & Haas Method for identifying and quantifying polymers utilizing immunoassay techniques
US6048527A (en) * 1996-08-27 2000-04-11 Chiron Corporation Antibodies that define unique Meningococcal B epitopes and vaccine compositions
DE69708318T3 (de) † 1996-08-27 2006-11-16 Novartis Vaccines and Diagnostics, Inc., Emeryville Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
US6426074B1 (en) 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
EP0994723A1 (en) 1997-06-24 2000-04-26 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
DE69840508D1 (de) * 1997-08-27 2009-03-12 Childrens Hosp Medical Center Molekular-mimetika von meningokokkus b epitopen
JP4435413B2 (ja) 1997-12-23 2010-03-17 バクスター・ヘルスケヤー・ソシエテ・アノニム ワクチンとしてまたは結合体ワクチンとしてタンパク質に連結して使用するための細菌莢膜多糖の抽出および単離法
CN1263510C (zh) * 1998-08-19 2006-07-12 巴克斯特健康护理股份有限公司 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用
RU2249463C2 (ru) * 1998-08-19 2005-04-10 Бакстер Хелфкэа С.А. Иммуногенный конъюгат бета-пропионамид-связанного полисахарида с белком, использующийся в качестве вакцины
US6436653B1 (en) 1998-12-15 2002-08-20 Exiqon A/S Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US6518037B2 (en) * 1999-11-12 2003-02-11 University Of Iowa Research Foundation Two-component system that controls bacterial membrane synthesis
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0011108D0 (en) * 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
JP2004529643A (ja) * 2001-04-17 2004-09-30 カイロン コーポレイション 機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
ES2616180T3 (es) * 2002-03-26 2017-06-09 Glaxosmithkline Biologicals Sa Sacáridos modificados con estabilidad mejorada en agua para su uso como medicamento
NZ536859A (en) * 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis
RU2364418C2 (ru) * 2002-08-02 2009-08-20 ГлаксоСмитКлайн Байолоджикалз с.а. ВАКЦИННЫЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ЛИПОПОЛИСАХАРИДЫ ИММУНОТИПА L2 И/ИЛИ L3, ПРОИСХОДЯЩИЕ ИЗ ШТАММА NEISSERIA MENINGITIDIS IgtB-
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
AU2004227852B2 (en) 2003-03-31 2010-01-14 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
EP1654290B1 (en) 2003-08-12 2019-03-13 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
EP1784428A2 (en) * 2004-06-23 2007-05-16 Children's Hospital & Research Center at Oakland Polysaccharide derivatives and uses in induction of an immune response
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
HUE045482T2 (hu) 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény
WO2007092451A2 (en) 2006-02-06 2007-08-16 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
GB0611914D0 (en) 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
EP1872791A1 (en) * 2006-06-30 2008-01-02 Institut Pasteur Use of bacterial polysaccharides for biofilm inhibition
CA2692069C (en) * 2007-06-20 2016-10-18 Baxter Healthcare S.A. Modified polysaccharides for conjugate vaccines
AU2008335457B2 (en) 2007-12-07 2015-04-16 Glaxosmithkline Biologicals S.A. Compositions for inducing immune responses
US9050283B2 (en) 2009-01-16 2015-06-09 University Of Maryland, Baltimore Broad spectrum vaccine against non-typhoidal Salmonella
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
EP2752403A1 (de) * 2013-01-08 2014-07-09 Sika Technology AG Amin für emissionsarme Epoxidharz-Produkte
CN108135167B (zh) 2015-08-19 2021-07-09 哈佛学院院长及董事 脂化psa组合物和方法
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
SG11201906519RA (en) * 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
RO111416B1 (ro) * 1989-12-14 1996-10-31 Ca Nat Research Council Polizaharide modificate de neisseria meningitidis si e coli, combinatii antigenice si metoda de imunizare

Also Published As

Publication number Publication date
EP0504202B1 (en) 1995-05-03
US5902586A (en) 1999-05-11
KR0158436B1 (ko) 1998-12-01
AU6898791A (en) 1991-07-18
FI104539B (fi) 2000-02-29
NO305275B1 (no) 1999-05-03
BR9007917A (pt) 1992-10-20
PH30305A (en) 1997-02-20
NZ236471A (en) 1992-10-28
NO973311D0 (no) 1997-07-17
SI20008B (en) 2001-02-28
CN1100656A (zh) 1995-03-29
PL166035B1 (pl) 1995-03-31
JP2637845B2 (ja) 1997-08-06
CN1055541A (zh) 1991-10-23
CN1072506C (zh) 2001-10-10
FI19991917L (fi) 1999-09-09
DE69019164T2 (de) 1995-09-07
CN1100428A (zh) 1995-03-22
RU2105568C1 (ru) 1998-02-27
CZ628490A3 (en) 1997-12-17
RO111416B1 (ro) 1996-10-31
FI19991917A7 (fi) 1999-09-09
IN171747B (es) 1992-12-26
ATE121947T1 (de) 1995-05-15
HU218146B (hu) 2000-06-28
CN1036504C (zh) 1997-11-26
HUT64480A (en) 1994-01-28
CA2071811A1 (en) 1991-06-15
CN1036522C (zh) 1997-11-26
PL288271A1 (en) 1991-12-16
AU641715B2 (en) 1993-09-30
SI20008A (sl) 2000-02-29
US5683699A (en) 1997-11-04
CA2071811C (en) 2003-11-04
NO307835B1 (no) 2000-06-05
HRP920872A2 (en) 1997-06-30
WO1991008772A1 (en) 1991-06-27
NO973311L (no) 1992-08-14
IE904513A1 (en) 1991-06-19
CZ283530B6 (cs) 1998-04-15
YU24391A (sh) 1995-12-04
DE69019164D1 (de) 1995-06-08
IL96676A (en) 1996-09-12
AR243934A1 (es) 1993-09-30
CN1049223C (zh) 2000-02-09
US5576002A (en) 1996-11-19
FI922737A0 (fi) 1992-06-12
NO922316L (no) 1992-08-14
ZA9010065B (en) 1992-02-26
CN1096516A (zh) 1994-12-21
PL166659B1 (pl) 1995-06-30
HU9201966D0 (en) 1992-10-28
JPH05505392A (ja) 1993-08-12
NO922316D0 (no) 1992-06-12
IL96676A0 (en) 1991-09-16
IE68414B1 (en) 1996-06-12
EP0504202A1 (en) 1992-09-23
DK0504202T3 (da) 1995-10-02

Similar Documents

Publication Publication Date Title
YU24391A (sh) Poboljšana meningokokna polisaharid kon-jugovana vakcina
Anderson et al. Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197.
JP3717511B2 (ja) サポニン−抗原複合物とその用途
PT939647E (pt) Glicpconjugados do serogrupo b de neisseria meningitidis e metodos de utilizacao dos mesmos
KR100431236B1 (ko) 2,5-안히드로-d-만노오스터미널구조를갖는항원성b족연쇄구균타입ⅱ및타입ⅲ다당류및그의복합백신
Cryz Jr et al. Safety and immunogenicity of a polyvalentKlebsiella capsular polysaccharide vaccine in humans
BR9510263A (pt) Novo derivado de ciclodextrina processo para sua preparação utilização dos mesmos composição terapêutica e adjuvante para vacinas
ES2152421T3 (es) Vacunas de conjugados polisacarido neumococcico-neumolisina recombinante para la inmunizacion contra las infecciones neumococcicas.
ES2059372T3 (es) Conjugados inmunogenos.
MC2178A1 (fr) Mutants de la pneumolysine et vaccins a base de pneumocoque prepares a partir de ces mutants
ATE120093T1 (de) Meningococcales klasse i-aussenmembranprotein- vakzin.
ES2145072T3 (es) Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos.
Sun et al. Ginsenoside Rg1 and aluminum hydroxide synergistically promote immune responses to ovalbumin in BALB/c mice
NO950739D0 (no) Vaksiner mot gruppe C Neisseria Meningtidis
FR2399252A1 (fr) Vaccin de masse moleculaire elevee contre la meningite a meningocoques du groupe c et procede pour sa preparation
Trzewikoswki de Lima et al. Study of the immune response in the elderly: is it necessary to develop a vaccine against Neisseria meningitidis for the aged?
ES2051909T3 (es) Vacuna del conjugado de polisacarido-proteina de membrana externa contra la haemophilus influenzae tipo b.
WO1996011709B1 (en) Synthesis of typhoid fever vaccine from a plant or fruit polysaccharide
Cabral-Hipólito et al. Tannic acid exhibits adjuvant activity by enhancing humoral and cell-mediated immunity against BSA as a protein antigen
Dzata et al. Immunopotentiation of cattle vaccinated with a soluble Brucella abortus antigen with low LPS content: an analysis of cellular and humoral immune responses
NO892015L (no) Fremgangsmaate for fremstilling av et legemiddel.
Landay et al. Serological comparison of the three morphological phases of Coccidioides immitis by the agar gel diffusion method
Fisher Enough nonsense on immunization
Alugupalli A TLR4 ligand-based adjuvant for promoting the immunogenicity of typhoid subunit vaccines
Bailey et al. The tissue specificity of brain and medullated nerves as shown by passive anaphylaxis in guinea pigs

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 504202

Country of ref document: ES